Invest Securities is maintaining its "neutral" rating on Medesis shares, with an unchanged target price of 3.3 euros, despite the company's announcement on Wednesday that it has entered into a safeguard procedure.

As a reminder, last May, the Montpellier Commercial Court ordered Medesis to pay the sum of €1.4 million to Bpifrance, with whom the company has been in dispute for many years.

This safeguard plan offers the company up to 12 months' respite, to enable it to put its financial situation on a sounder footing, identify a potential partner and work out a solution with Bpifrance.

Where peril grows, there also grows that which saves... ', philosophizes the analyst, who therefore confirms his recommendation on the stock.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.